NBI-1065846 (TAK-041)

NBI-1065846 (TAK-041) is being developed by Neurocrine Biosciences and Takeda Pharmaceutical Company Limited as part of a strategic collaboration announced in June 2020. The compound is a potential first-in-class GPR139 agonist for the treatment of anhedonia in depression. Neurocrine Biosciences plans to initiate a Phase II study of NBI-1065846 in patients with anhedonia in depression in 2021.